Feedback / Questions
amlitelimab IV (SAR445229) - Sanofi
amlitelimab SC (KY1005 SC) - Sanofi
Amlitelimab: Regulatory submission for atopic dermatitis in 2027
(Sanofi)
-
Apr 26, 2024 -
Q1 2024 Results
Regulatory
•
Atopic Dermatitis • Dermatology • Immunology
https://www.sanofi.com/assets/dotcom/content-app/events/quaterly-results/2024/2024-q1-2024-results/q1-2024-presentation-en.pdf
Apr 26, 2024
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious